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Abstract
Background: Approximately 20 % of obese dogs have metabolic disturbances similar to those observed in human
metabolic syndrome, a condition known as obesity-related metabolic dysfunction. This condition is associated with
insulin resistance and decreased circulating adiponectin concentrations, but clinical consequences have not been
reported. In order to define better the metabolic changes associated with obesity-related metabolic dysfunction
(ORMD), we compared the plasma proteomes of obese dogs with and without ORMD.
A proteomic analysis was conducted on plasma samples from 8 obese male dogs, 4 with ORMD and 4 without
ORMD. The samples were first treated for the depletion of high-abundance proteins and subsequently analysed by
using 2-DE DIGE methodology.
Results: Using mass spectrometry, 12 proteins were identified: albumin, apoliprotein A-I, C2, C3, C5, C4BPA, A2M,
Uncharacterised protein (Fragment) OS = Canis familiaris, fibrinogen, IGJ, ITIH2, and glutathione peroxidase. In
obese dogs with ORMD, the relative amounts of ten proteins (albumin, apoliprotein A-I, C2, C3, C5, C4BPA, A2M,
Uncharacterised protein (Fragment) OS = Canis familiaris, fibrinogen, and ITIH2) were increased and two proteins
(IGJ and glutathione peroxidase) were decreased, compared with obese dogs without ORMD. Specific assays were
then used to confirm differences in serum albumin, apoliprotein A-I and glutathione peroxidase in a separate group
of 20 overweight dogs, 8 with ORMD and 12 without ORMD.
Conclusions: The current study provides evidence that, in obese dogs with ORMD, there are changes in expression
of proteins involved in lipid metabolism, immune response, and antioxidant status. The clinical significance of these
changes remains to be defined.
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Background
In humans metabolic syndrome (MetS) is an extensively
studied entity that comprises obesity, hypertension, dys-
lipidaemia, and glucose intolerance [1], and is associated
with the development of cardiovascular disease and type
2 diabetes [2]. The prevalence of metabolic syndrome in
humans varies with age and ethnic groups, and it has
been estimated that one-quarter of the world’s adult
population has the MetS [1]. Recently, when human
MetS criteria were adapted for dogs to define the condi-
tion of obesity-related metabolic dysfunction (ORMD),
approximately 20 % of dogs with naturally occurring
obesity were described as presenting with concurrent
ORMD [3]. The presence of ORMD was associated with
increased circulating insulin and decreased adiponectin
concentrations, suggesting that ORMD might be associ-
ated with a range of metabolic disturbances. However, to
date, no study has identified any direct association between
these disturbances and clinical diseases of obese dogs, such
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that the pathophysiological significance of the changes that
occur in ORMD remains unknown.
Proteomic analysis has been increasingly used in
human medicine and experimental animals in order to
evaluate possible changes in blood, adipose tissue, or adi-
pocyte proteomes in obese subjects [4–7], with the aim of
identifying and clarifying the underlying mechanisms re-
sponsible for development of secondary diseases. To the
authors’ knowledge, the only proteomic study to date in
canine obesity was performed under experimental condi-
tions, and identified three proteins (retinol binding protein
4, clusterin, and α-1 antitrypsin) that differed between
obese and lean dogs [3]. Whilst this study demonstrated
proof of principle, it is possible to refine the technique re-
ported and improve detection sensitivity by first depleting
high-abundance protein species in the biological samples
examined [8]. Such a depletion technique has been
performed in some human proteomic studies of obesity
[9, 10]. In addition, when comparing protein differences
between two samples, fluorescence two-dimensional dif-
ferential gel electrophoresis (2-DE DIGE) has shown bene-
fits over conventional 2-DE methodology, since it enables
two different samples to be run on the same gel in both
dimensions thus minimising gel-to-gel variation [11, 12].
The main objective of the current study was to compare
the plasma proteomes of obese dogs with and without
ORMD in order to evaluate if the presence of ORMD
imply changes in proteome of obese dogs.
Methods
Animals
The study protocol adhered to the University of Liverpool
Animal Ethics Guidelines, and was approved by both the
University of Liverpool Research Ethics Committee and
the WALTHAM Animal Welfare & Ethical Review Board.
All clinical procedures were performed for the direct
benefit of the animals, and their owners gave informed
written consent.
Plasma samples from eight neutered male obese dogs
(group 1; 4 with ORMD, and 4 without ORMD) were
used in the proteomic study. All dogs were originally re-
ferred to the Royal Canin Weight Management Clinic,
University of Liverpool UK for investigation and manage-
ment of obesity. Any surplus plasma, after that required
for use in routine clinical biochemical analyses, was frozen
at −20 °C, usually within 30 min of sample collection.
All samples remained frozen until shipment on dry ice to
the Interlab-UMU, Murcia, Spain, where all proteomic
analyses were conducted.
In order to corroborate the proteomic analysis findings
serum samples from a further 20 dogs (group 2) from
different private veterinary clinics of Murcia Region,
Spain, were used. Twelve dogs were overweight/obese
without ORMD and eight overweight/obese with ORMD.
These dogs were otherwise healthy as recorded on
physical examination, CBC and biochemistry analyses.
All procedures were approved by the Ethics Committees
of University of Murcia and Murcia Region; in addition,
an informed consent was obtained from the owner before
inclusion of the dog in the study.
Clinical measurements
Body condition score was determined using a validated
9-point body condition score system in both groups
[13, 14]. In addition for group 1 dogs, body composition
was analysed using fan-beam DEXA (Lunar Prodigy
Advance; GE Lunar) [15–17]. Blood pressure in all dogs
was measured non-invasively using an oscillometric
method. All dogs were fully conscious. A cuff of the ap-
propriate size (e.g. the cuff chosen had a width of ~40 %
circumference of the leg) was placed on the right forelimb.
Once the dog was calm and still, at least five systolic blood
pressure (SBP) readings were taken and averaged. Finally,
blood samples were collected by jugular venepuncture
after a fast of at least 16 h.
Definition of obesity-related metabolic dysfunction
Dogs were considered as having ORMD if the following
criteria were met: (a) BCS 7-9/9; AND (b) any two of
the following: 1) plasma triglycerides > 2.3 mmol/L; 2)
plasma cholesterol > 7.8 mmol/L; 3) SBP > 160 mmHg; 4)
fasting plasma glucose > 5.6 mmol/L, or previously diag-
nosed diabetes mellitus [3].
Dog plasma pre-treatment (ProteoMiner)
Plasma samples from group 1 dogs were treated with
ProteoMiner treatment according to manufacturer’s rec-
ommendation (BioRad Laboratories, Hercules, CA.).
Briefly, 20 μL aliquots of ProteoMiner beads (small cap-
acity kit) were equilibrated with washed buffer (phosphate
buffer saline (PBS): 150 mM NaCl, 10 mM NaH2PO4,
pH 7.4). Subsequently, 200 μL plasma samples were
applied and incubated for 2 h at room temperature
under constant rotation. After incubation, the beads
were washed three times with 200 μL wash buffer to
remove unbound proteins. Bound proteins were eluted
with three washes of 20 μL elution reagent (8 M urea, 2 %
CHAPS). Eluted proteins were cleaned using 2D clean-up
kit (GE Healthcare Europe GmbH, Freiburg, Germany)
and resuspended in rehydration buffer (30 mmol/L
Tris basic, 2 mol/L thiourea, 7 mol/L urea, 4 % wt/vol
CHAPS).
Protein sample preparation and fluorescence labelling
Protein concentration was determined with 2Dquant kit
(GE Healthcare Europe GmbH, Freiburg, Germany). The
DIGE fluors –N-hydroxysuccinimidyl ester derivatives of
the cyanine dyes, Cy2, Cy3 and Cy5 (GE Healthcare
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Europe GmbH, Freiburg, Germany) –were prepared
using freshly opened N,N-dimethylformamide (Sigma-
Aldrich). Protein samples (50 μg) were labelled with 400
pmol of Cy2, Cy3 and Cy5 DIGE fluors in separate tubes
on ice for 30 min. An internal standard was created by
mixing equal amounts of proteins of all samples and label-
ling it with Cy2, whereas individual samples were labelled
with Cy3 and Cy5. The labelling reaction was quenched
by adding 1 μL of 10 mmol/L lysine.
Two-Dimensional DIGE
The immobilised pH gradient strips (pH 4–7; GE
Healthcare Europe GmbH, Freiburg, Germany) were ac-
tively rehydrated for 16 h according to the instructions
of the manufacturer. The Cy2-labelled internal standard
of pooled samples was used to minimise experimental
gel-to-gel variation and to facilitate cross-gel quantitative
analysis. Equal amounts (50 μg protein per dye per gel)
of Cy3- and Cy5-labelled individual samples and the
Cy2-labeled internal standard were mixed together and
loaded onto an 18-cm immobilised pH gradient strip
(pH 4–7). The proteins were focused in the first dimen-
sion for a total of 60000 Vh in the Ettan IPGphor 3 sys-
tem (GE Healthcare Europe GmbH, Freiburg, Germany).
The immobilised pH gradient strips were equilibrated
first in buffer I [6 mol/L urea, 2 % SDS, 75 mmol/L Tris
(pH 8.8), 30 % glycerol, 1 % DTT] for 15 min and then
in buffer II (same as buffer I plus 2.5 % iodoactamide)
for 15 min and subsequently transferred onto 12.5 %
gels. Proteins were then separated in the second dimen-
sion based on their molecular weight in the Ettan DALT
six (GE Healthcare Europe GmbH, Freiburg, Germany). A
total of six SDS gels were run together at 5 mA per gel for
2 h and 2 W per gel for 12 h with the temperature of the
running buffer maintained at 23 °C.
Image acquisition and analysis
Gels were scanned directly between glass plates at 488/
520 nm, 532/580 nm and 633/670 nm (excitation/emis-
sion wavelengths) for the Cy2, Cy3 and Cy5 signals, re-
spectively, using a Typhoon 9410 fluorescent scanner
(GE Healthcare Europe GmbH, Freiburg, Germany).
Raw data of images were analysed with DeCyder 7.0
software (GE Healthcare Europe GmbH, Freiburg,
Germany). Briefly, original images of Cy2, Cy3 and Cy5
images for each gel were cropped and smoothed to clar-
ify spots. The software was used following manufacturer
recommendations, and the estimated number of spots
was set to 1500. The internal standard image with the
most detected spots was assigned as the master and it
was selected to create a MatchSet image. A MatchSet
image was created for comparing and analysing spots
from all 11 images and a master image. The Cy2 spot data
from each gel were normalised on a spot-to-spot basis
using respective Cy3 and Cy5 signals of the internal stand-
ard from the same gel, and the normalised Cy2 signal was
then used for spot intensity comparison and analysis. The
protein abundance for each spot in each sample was then
expressed as a ratio relative to the internal standard. Stat-
istical analysis was performed for every matched spot set,
comparing the average ratio for a given spot between
groups. Only those spots with a p < 0.05 and a fold change
greater than 1.5 and lower than −1.5 were considered.
Preparatives 2D gel
Preparative gel, containing 275 μg of protein, were pre-
pared for a mix used as internal standard using PlusOne™
Bind-Silane following manufacturer recommendations (GE
Healthcare Europe GmbH, Freiburg, Germany). These gels
were fixed and stained with Colloidal Coomassie G-250
following the previously described protocol [18]. The im-
ages were then captured using the Image Scanner III Sys-
tem (GE Healthcare Europe GmbH, Freiburg, Germany).
The desired protein spots were picked from the Coomassie
stained gels with Ettan Spot Picker (GE Healthcare Europe
GmbH, Freiburg, Germany).
Protein identification
Proteins within gel spots were first reduced and alky-
lated using DTT and iodoacetamide, respectively, and
then digested to peptides by trypsin proteomics grade
(Sigma-Aldrich, St Louis, MO, USA) [19].The tryptic
peptides were analysed by capillary reverse-phase liquid
chromatography coupled online with MS/MS. The column,
BioBasic-18, 5 μm particles, 300 Å pore size, 0.18 mm ID-
100 mm L (Thermo, San Jose, CA), was connected to a
Surveyor MS Pump Plus (Thermo, San Jose, CA) and then
coupled with an ion trap mass spectrometer (LXQ,
Thermo, San Jose, CA). The flow rate was set at 180 μl/min
but split to a flow rate of 2 μl/min. Mobile phase A was
0.1 % formic acid/2 % methanol in water and B was 0.1 %
formic acid in methanol. The peptide samples were injected
and gradient elution was done under the following condi-
tions: 5 % B in 2 min; a linear increase of 5 to 70 % B in
20 min; 70 % for 10 min; 5 % B for 10 min. The ion trap
MS was operated in a data-dependent MS/MS mode where
the five most abundant peptide molecular ions in every MS
scan were sequentially selected for collision-induced
dissociation with a normalised collision energy of 34 %.
Dynamic exclusion was applied to minimise repeated
selection of peptides previously selected for collision in-
duced dissociation. The capillary temperature and electro-
spray voltage were set to 200 °C and 3.5 kV, respectively.
The resulting mass spectra were searched against the
Canis familiaris Uniprot database (26456 sequences,
released at September 19, 2013) with the Proteome
Discoverer 1.3 software (Thermo, San Jose, CA). The
following search parameters were applied: default charge
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states of 2+, 3+, and 4+ were used; a maximum of one
missed cleavage was allowed with an average peptide mass
tolerance of 1.5 Da. A fragment ion search tolerance of
0.8 Da was permitted. Fixed modification on cysteine was
carbamidomethylation and a variable modification was
oxidation of methionine. All data were searched against a
decoy database. The peptide concentration score cut-off
for each of the runs was automatically adjusted to ensure
a 1 % false discovery rate throughout the experiments. A
positive identification was assigned when two or more
unique peptides were identified.
Verification of proteomic analysis by specific assays
Serum samples from group 2 dogs were analysed for
albumin (Albumin, Beckman Coulter Ireland Inc.,
Lismeehan, Ireland), apoliprotein A-1 (Apoliprotein A-I
(APO A-I), BioSystems, Barcelona, Spain), and glutathione
peroxidase (Ransel, Randox Laboratories Limited, Crumlin,
United Kingdom). All the methods were performed in
automated analyzer (Olympus AU600, Beckman Coulter,
Brea, USA). All assays showed an inter- and intra-assay
imprecision less than 15 % and a linearity under dilution
resulted in coefficient of correlation close to 1 with canine
serum samples.
Statistical analysis
Statistical analysis was performed using routine descrip-
tive statistical procedures and software (Graph Pad Prism,
Version 5). In order to compare different variables be-
tween dogs with and without ORMD of the group 2, the
data were first evaluated for normality of distribution
using a D’Agostino & Pearson omnibus normality test, giv-
ing not parametric distribution. For this, Mann–Whitney
test was performed. Values of P < 0.05 were considered
significant.
Results
Comparison of obese dogs with and without ORMD
The baseline characteristics of group 1 dogs with and
without ORMD (participating in proteomic analyses) are
shown in Table 1, with no marked differences between
the groups, in terms of age, breed, weight, and body fat
percentage. All 4 dogs with ORMD had increased SBP,
whilst 3, 3, and 2 dogs, respectively, had increased glucose,
cholesterol, and triglyceride concentrations.
The baseline characteristics of group 2 dogs the animals
with and without ORMD (used for assay verification) are
shown in Table 2. Again, there were no marked differ-
ences between the groups, in terms of age, breed, and
weight. Of the 8 dogs with ORMD, five had hypercholes-
terolaemia, four had hypertriglyceridaemia, and six had
hyperglycaemia. Of the 12 dogs without ORMD, two
had hypercholesterolaemia, one had hypertriglyceridae-
mia, and two had hyperglycaemia.
Table 1 The baseline characteristics of dogs included in
proteomic study with and without obesity-related metabolic
dysfunction (ORMD)
Variable ORMD No ORMD
Sex 4 males (all neutered) 4 males
(all neutered)
Age, months 60 (25–120) 70 (43–120)
Breed Labrador Retriever (2),
Golden Retriever;
Patterdale terrier
Border Terrier
Labrador
Mixed Breed
Newfoundland
Weight, kg 36.7 (13.8–100.0) 49.6 (25.8–60.8)
Total BodyFat, % 52.4 (50.8–60.8) 52.1 (44.4–55.1)
BCS 9 (9–9) 9 (7–9)
SBP, mmHg 174 (166–177) 141 (123–159)
Glucose, mmol/L 5.6 (5.1–6.0) 5.3 (4,8–5,5)
Cholesterol, mmol/L 6.9 (4.6–8.0) 5.9 (4,9–6,1)
TG, mmol/L 1.3 (0.8–2.3) 0.8 (0.5–1.2)
Data are presented as median (interquartile range)
BCS body condition score, SBP systolic blood pressure, TG triglycerides
Table 2 The baseline characteristics of dogs included in
proteomic study verification with and without obesity-related
metabolic dysfunction (ORMD)
Variable ORMD No ORMD P
Number 8 12
Sex 3 males and 5 females
(all neutered)
5 males and 7 females
(all neutered)
Age, months 100 (36–139) 81 (24–132) NS
Breed Mixed Breed (2), Mixed Breed (7)
Boxer, Yorkshire terrier (2)
Beagle, Bichon Maltese
Brittany Spaniel Collie
Cocker Spaniel, Shih tzu
French Bulldog,
Yorkshire terrier,
Weight, kg 12.4 (11.4–18.7) 20.3 (5.2–44.5) NS
BCS 9 (8–9) 9 (7–9) NS
SBP, mmHg 140 (123–150) 130 (110–158) NS
Glucose, mmol/L 5.8 (5.7–7.6) 4.9 (4.7–5.3) 0.047
Cholesterol,
mmol/L
9.1 (7.6–11.0) 5.8 (5.2–7.6) 0.007
TG, mmol/L 2.8 (0.8–3.8) 0.9 (0.6–1.4) NS
Data are presented as median (interquartile range)
BCS body condition score, SBP systolic blood pressure, TG triglycerides, NS not
statistically significant
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Proteomic analysis
More than 1200 individual spots, ranging from 15 to
250 kDa masses over pH 4–7 were detected in gels of
protein mapping of canine plasma pre-treated with Pro-
teoMiner. Using image analysis and further statistical
analysis, 8 spots were detected and subsequently identi-
fied with differential protein concentrations between
dogs with and without ORMD (Fig. 1). Among these 8
protein spots, protein concentrations were increased in
3 and decreased in 5 obese dogs with ORMD compared
with obese dogs without ORMD (Table 3, Fig. 2).
Mass spectrometry
Mass spectrometry allowed the identification of 12 pro-
teins from seven out of eight spots detected (Table 4),
which were identified as: alpha-2 macroglobulin (A2M)
and, apoliprotein A-I (spot number 268), C2 and C5(spot
410), fibrinogen and Uncharacterised protein (Fragment)
OS =Canis familiaris (spot 624), albumin (spot 730), C3
(spots 730, 736 and 1190), ITIH2 (spots 730. 736 and
1190), C4BPA (spot 1190), IGJ(spot 1199), and glutathione
peroxidase (spot 1201). Unfortunately, the proteins in spot
1205 could not be identified. Among these 12 proteins,
concentrations were increased in 10 and decreased in 2
in obese dogs with ORMD compared with obese dogs
without ORMD. The proteins with increased expression
in ORMD were: albumin, apoliprotein A-I, C2, C3,
C5, C4BPA, A2M, Uncharacterised protein (Fragment)
OS = Canis familiaris, fibrinogen, and ITIH2, whilst
the two proteins with decreased expression in ORMD
were: IGJ and glutathione peroxidase.
Verification of proteomic analysis by specific assays
Specific assays were used to verify the results of proteomic
analyses in a separate group of dogs. Plasma albumin
(P = 0.044) and apoliprotein A-I (P < 0.001) concentra-
tions were greater in dogs with ORMD, and there
was also decreased activity of glutathione peroxidase
(P = 0.039) (Fig. 3).
Discussion
The aim of the present study was to evaluate differ-
ences in the plasma proteome of obese dogs with and
without ORMD. For this, we used 2D DIGE and mass
spectrometry to identify a set of proteins that differed
significantly in abundance in the plasma of obese dogs
with ORMD relative to obese dogs without ORMD. In
total, 12 differentially expressed proteins were identified.
These were proteins associated with lipid metabolism
(albumin, apoliprotein A-I), the complement system
(C2, C3, C5, C4BPA, A2M, Uncharacterised protein
(Fragment) OS =Canis familiaris), coagulation (fibrinogen),
immune response (IGJ), hyaluronan metabolic process
(ITIH2), and antioxidants (glutathione peroxidase). These
findings provide further evidence that ORMD in dogs is as-
sociated with a range of metabolic changes, although their
clinical significance remains unknown.
Increased albumin abundance was observed in the
plasma of obese dogs with ORMD compared with dogs
without ORMD by both proteomic and specific analysis.
Significantly greater albumin concentrations have previ-
ously been reported in obese compared with healthy
dogs [20], and circulating concentrations of albumin are
known to decrease after weight loss [17, 20]. However,
not all studies have identified such differences [21, 22].
That said, increased albumin expression has been de-
tected in the proteome of mature adipocytes collected
from overweight and morbidly obese persons [7]. Fur-
ther studies would be indicated in order to determine
Fig. 1 Representative 2-DE gel images proteins of ProteoMiner pre-treated plasma samples obtained from dogs with and without obesity-related
metabolic dysfunction (ORMD). Differentially expressed protein spots between the dogs with and without ORMD are circled and numbered
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the mechanisms involved for the increased circulating
albumin in obese dogs with ORMD.
Apolipoprotein A1 (APO-A1) participates in the re-
verse transport of cholesterol from tissues to the liver,
ready for its subsequent excretion. APO-A1 has also
been reported to have acyl coenzyme A cholesterol
acyltransferase-like activity; this may synergistically regu-
late adipogenesis and lipid metabolism [23]. In the
current study, greater APO-A1 concentrations were de-
tected in dogs with ORMD as observed in proteomic
analysis and verified by a specific assay. These results are
consistent with those reported by Briand et al. [24] who,
in a stable isotope study, observed increased APO-A1
production in insulin resistant dogs.
In the present study, six different proteins (C2, C3, C5,
C4BPA, A2M, Uncharacterised protein (Fragment) OS =
Canis familiaris) associated with the complement arm
of the immune system were higher in abundance in dogs
with ORMD. In two human proteomics studies, plasma
C3 was identified as a key marker for differences in body
fat and body fat changes [10, 27]. Further, in humans C3
was associated with the prevalence of MetS and diabetes
mellitus type 2 development [25]. It was speculated that
increased concentrations of proteins of complement sys-
tem could be due to decreased activity of the comple-
ment system or due to changes in production in adipose
tissue or at other sites [10, 26]. Similar mechanisms
might be responsible for the findings in obese dogs with
ORMD, but more work would be required to clarify this.
Dogs with ORMD also had greater fibrinogen concen-
trations than dogs without ORMD. It has been suggested
fibrinogen to be an additional defining component of
metabolic syndrome in humans [28], as fibrinogen con-
centrations were increased in subjects with metabolic
syndrome compared with those without it [28, 29]. It
has been hypothesised that fibrinogen acts as a link be-
tween prothrombotic and proinflammatory states in
metabolic syndrome in humans [28].
J-chain of immunoglobulin (IGJ) is a protein of about
15 kDa polypeptide, expressed by mucosal and glandular
plasma cells. It regulates polymer formation of immuno-
globulin (Ig) A and IgM. In humans increased IgA con-
centration is associated with components of metabolic
Table 3 Fold change of differentially expressed spot matches in
dogs with (n = 4) and without (n = 4) obesity-related metabolic
dysfunction (ORMD)
Spota Fold change noORMD dogs/ORMD dogs P
1205 42.68 0.017
1201 2.55 0.005
1199 1.53 0.006
410 −1.76 0.040
268 −2.08 0.041
730 −2.28 0.036
624 −2.39 0.009
736 −3.09 0.031
aSpot label number from annotated gel image (see Figs. 1 and 2)
Fig. 2 Example of the 3-dimensional images of differentially regulated spot proteins (one increased and one decreased) in dogs with (left) and
without (right) obesity-related metabolic dysfunction (ORMD). Graphics represent the changes in Standardised Abundance of specific spots after
logarithmic transformation obtained directly from DeCyder 7.0 software analysis: dotted lines represent individual data, entire lines represent mean
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syndrome, such as hyperglycaemia, hypertriglyceridaemia,
and abdominal obesity [30]. It has been suggested that in-
creased IgA and IgM concentrations could be attributed
to the presence of low-grade inflammation in obesity [30].
Taken together, it could be hypothesised that lower abun-
dance of IGJ observed in dogs with ORMD in present
study, could be attributed to its greater utilisation by IgA
or/and IgM. However, future studies are required in order
to clarify this.
The inter-alpha (globulin) inhibitor (ITI) family (more
commonly called the family of inter-alpha-trypsin inhibi-
tors) is composed of serine protease inhibitors that are
assembled from two precursor proteins: a light chain and
either one or two heavy chains [31, 32]. Whilst there is
only one type of light chain, to date, five different
homologous heavy chains (ITIHs) have been identified in
this family (ITIH1-ITIH5) [33]. The only currently known
function of the heavy chains is to bolster the stability of
extracellular matrix through covalent linkage to hyalur-
onic acid [34], which is a major component of this matrix
[33].A number of studies have reported on the biological
effects of the ITI molecules, proposing involvement in
various acute-phase processes, such as inflammation or
cancer [33, 35]. ITIH2 was shown to be down-regulated in
tumours of the breast, compared with other ITIH pro-
teins, suggesting its potential function as tumour suppres-
sor or metastasis repressor [33]. In the present study,
increased abundance of ITIH2 was observed in obese dogs
with ORMD and, to the authors’ knowledge, no previous
studies have linked this protein to metabolic syndrome.
Table 4 Mass spectrometry identification of proteins
Spot Noa Protein name Accession numberb Score Unique peptides Sequence
coverage (%)c
MW (kDa)/pI
268 Uncharacterised protein Canis familiaris (A2M) F6UME0 99.79 10 8.14 165.1/6.71
Apolipoprotein A-I Canis familiaris F1PDJ5 11.42 2 9.40 30.2/5.39
410 Uncharacterised protein Canis familiaris (C2) E2RS75 132.97 9 16.56 86.3/7.37
Uncharacterised protein Canis familiaris (C5) F1P7J4 18.61 2 1.36 188.5/6.60
624 Fibrinogen alpha chain OS = Canis familiaris J9NRV7 112.52 5 7.05 88.9/6.16
Uncharacterised protein (Fragment) OS = Canis familiaris F1PWR2 12.25 3 2.45 192.8/6.89
730 Uncharacterised protein Canis familiaris (C4BPA) F1PGM9 390.27 11 30.93 57.9/6.83
Albumin Canis familiaris F2Z4Q6 174.32 8 15.30 68.6/5.69
Uncharacterised protein Canis familiaris (C3) F1PGM1 64.87 5 2.81 176.0/7.12
Uncharacterised protein Canis familiaris (ITIH2) F1PG39 4.96 3 4.96 107.2/7.53
736 Uncharacterised protein Canis familiaris (C4BPA) F1PGM9 456.80 8 23.93 57.9/6.83
Uncharacterised protein Canis familiaris (ITIH2) F1PG39 237.71 6 11.39 107.2/7.53
Uncharacterised protein Canis familiaris (C3) F1PGM1 128.64 11 8.62 176.0/7.12
Albumin Canis familiaris F2Z4Q6 38.31 2 5.59 68.6/5.69
1199 Uncharacterised protein Canis familiaris (IGJ) J9JHH5 43.95 2 12.58 18.2/4.82
1201 Glutathione peroxidase (Fragment) Canis familiaris J9P028 322.78 4 37.91 17.3/7.97
MW molecular weight
aSpot label number from annotated gel image (see Figs. 1 and 2). Spot No 1205 Not identified
bUniProtKB database. Canis familiaris(26456 sequences, 15304077 residues, 09/19/2013)
cSequence coverage: percentage of identified sequence to the complete sequence of the known protein
Fig. 3 Serum albumin, apoliprotein A-I, and gluthatione peroxidase in dogs with (ORMD; n = 8) and without (Non-ORMD; n = 12) obesity related
metabolic dysfunction (ORMD)
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Glutathione peroxidase is an 80 kDa protein, which is
composed of four identical subunits, and acts as a major
antioxidant in the plasma [35]. Decreased glutathione
peroxidase abundance was observed by proteomic
study in obese dogs that presented with ORMD. These
findings were also confirmed by use of a specific assay.
During the development of obesity, glutathione perox-
idase precursor expression decreases in obesity-prone
rats, but increases in both obesity-resistant and nor-
mal rats [35]. It was hypothesised that these changes
could lead to augmented systemic oxidative stress and
the onset of metabolic complications such as diabetes
mellitus [36].
The main limitation of the present study was the rela-
tively small number of animals studied by proteomic ana-
lysis. In light of this, only samples from male dogs were
used to perform proteomic analysis, so there could be no
possible confounding effect of sex or/and hormones. Pre-
vious studies have suggested that three biological samples
are sufficient to detect induced biological variations in the
proteome of animals [37, 38]. A second potential limita-
tion of the present study relates to storage of the samples
used for proteomic analysis prior to their transportation
to InterLab-UMU, Spain. It is possible that such storage
may have affected the results, for instance by resulting in
fewer spots/proteins being detected. Thirdly, the included
animals were client-owned dogs with variable living condi-
tions and different diets, what could have influenced the
results of the study. Nevertheless, the data are representa-
tive of a true clinic picture. Despite these limitations and,
although ideally all identified proteins should have been
validated, the verification of three proteins agrees with the
data observed by proteomic study.
Conclusions
The results of this comparative plasma proteome ana-
lysis have demonstrated that the obese dogs with ORMD
have alterations in the concentrations of proteins related
to lipid metabolism, immune response, and antioxidant
system. Further studies should be performed to evaluate
the clinical implications that changes in these proteins
could have.
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